Alternative Data for Tonix Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 25 | Sign up | Sign up | Sign up |
| Sentiment | 80 | Sign up | Sign up | Sign up |
| Webpage traffic | 16,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 12 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,014 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 256 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 82,174 | Sign up | Sign up | Sign up |
| X Followers | 8,488 | Sign up | Sign up | Sign up |
| X Mentions | 7 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 142 | Sign up | Sign up | Sign up |
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering.
| Price | $17.93 |
| Target Price | Sign up |
| Volume | 219,730 |
| Market Cap | $190M |
| Year Range | $14.08 - $61.57 |
| Dividend Yield | 0% |
| PE Ratio | 0.06 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Tonix Eyes TNX‑102 SL Expansion, But We Need To See Tonmya Revenue FirstJanuary 19 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 3.3M | 1.4M | 1.9M | -32M | -32M | -3.590 |
| Q2 '25 | 2M | 3.3M | -1.3M | -28M | -28M | -3.860 |
| Q1 '25 | 2.4M | 940,000 | 1.5M | -17M | -16M | -2.642 |
| Q4 '24 | 2.6M | 1.2M | 1.4M | -22M | -22M | -9.767 |
| Q3 '24 | 2.8M | 1.6M | 1.3M | -14M | -15M | -0.229 |
Insider Transactions View All
| Taylor Carolyn E. filed to buy 418 shares at $36. August 21 '25 |
| Treco James filed to buy 250 shares at $36. August 20 '25 |
| LEDERMAN SETH filed to buy 4,005 shares at $21.6. May 15 '25 |
Similar companies
Read more about Tonix Pharmaceuticals (TNXP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Tonix Pharmaceuticals
The Market Cap of Tonix Pharmaceuticals is $190M.
As of today, Tonix Pharmaceuticals' PE (Price to Earnings) ratio is 0.06.
Currently, the price of one share of Tonix Pharmaceuticals stock is $17.93.
The TNXP stock price chart above provides a comprehensive visual representation of Tonix Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tonix Pharmaceuticals shares. Our platform offers an up-to-date TNXP stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Tonix Pharmaceuticals (TNXP) does not offer dividends to its shareholders. Investors interested in Tonix Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Tonix Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
